C 038: ECONOMIC EVALUATION AND ORPHAN DRUGS

J Pharm Pharmacogn Res 2(Suppl. 1): S109, 2014

Special supplement with the abstract book of LATINFARMA 2013

Conference

C 038: ECONOMIC EVALUATION AND ORPHAN DRUGS

Gálvez González AM.

Escuela Nacional de Salud Pública de Cuba, La Habana, Cuba.
Abstract

Introduction: Orphan drugs financing decisions are related with different criterion. Literature reports various papers explaining the importance of economical assessment on orphan drugs designed to treat rare diseases.

Objective: The main goal of this paper is to highlight the importance of economic evaluation of orphan drugs for the decision making and its complexity in different context.

Method: A review of literature was done employing Big 6 model for the information competences management. Consults to experts in pharmacoeconomy, family doctors and decision makers in drugs area were done.

Results: The economic analysis of orphan drugs is a public health problem. Presently, it is a theme exposed in different space of discussion. Other economical items are important too, for example, to guarantee the equitative access to orphan drugs, the importance of enhance the knowledge in professionals about this subject, costs analysis , burden of rare diseases, financing and budgetary impact of orphan drugs. Finally international cooperation is identified as a key to develop future studies.